Literature DB >> 21671868

Prodrugs - an efficient way to breach delivery and targeting barriers.

Kristiina M Huttunen1, Jarkko Rautio.   

Abstract

The study of prodrugs that are chemically modified bioreversible derivatives of active drug compounds to alter their undesired properties has been expanded widely during the last decades. Despite the commercial success the prodrugs have afforded, the concept is still quite unknown among many scientist. Furthermore, many scientists regard prodrugs as a pure interest of academic research groups and not as a feasible solution to improve the delivery or targeting properties of new chemical entities, drug candidates failed in clinical trials, or drugs withdrawn from the market. Although there are still unmet needs that require addressing, prodrugs should be seen as fine-tuning tools for the successful drug research and development. This review represents the potential of prodrugs to improve the drug delivery by enhanced aqueous solubility or permeability as well as describes several targeted prodrug strategies.

Mesh:

Substances:

Year:  2011        PMID: 21671868     DOI: 10.2174/156802611797183230

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  15 in total

Review 1.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

Review 2.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

Review 3.  Drug delivery systems, CNS protection, and the blood brain barrier.

Authors:  Ravi Kant Upadhyay
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

Review 4.  The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture.

Authors:  Howard E Gendelman; JoEllyn McMillan; Aditya N Bade; Benson Edagwa; Bhavesh D Kevadiya
Journal:  Trends Microbiol       Date:  2019-04-10       Impact factor: 17.079

5.  An FtsZ-targeting prodrug with oral antistaphylococcal efficacy in vivo.

Authors:  Malvika Kaul; Lilly Mark; Yongzheng Zhang; Ajit K Parhi; Edmond J Lavoie; Daniel S Pilch
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

Review 6.  Mannich bases in medicinal chemistry and drug design.

Authors:  Gheorghe Roman
Journal:  Eur J Med Chem       Date:  2014-10-30       Impact factor: 6.514

7.  Protease-activated drug development.

Authors:  Ki Young Choi; Magdalena Swierczewska; Seulki Lee; Xiaoyuan Chen
Journal:  Theranostics       Date:  2012-02-08       Impact factor: 11.556

8.  Design of prodrugs to enhance colonic absorption by increasing lipophilicity and blocking ionization.

Authors:  Rebecca Nofsinger; Sophie-Dorothee Clas; Rosa I Sanchez; Abbas Walji; Kimberly Manser; Becky Nissley; Jaume Balsells; Amrithraj Nair; Qun Dang; David Jonathan Bennett; Michael Hafey; Junying Wang; John Higgins; Allen Templeton; Paul Coleman; Jay Grobler; Ronald Smith; Yunhui Wu
Journal:  Pharmaceuticals (Basel)       Date:  2014-02-24

Review 9.  Glutathione S-conjugates as prodrugs to target drug-resistant tumors.

Authors:  Emma E Ramsay; Pierre J Dilda
Journal:  Front Pharmacol       Date:  2014-08-11       Impact factor: 5.810

10.  Inhibitors for the hepatitis C virus RNA polymerase explored by SAR with advanced machine learning methods.

Authors:  Iwona E Weidlich; Igor V Filippov; Jodian Brown; Neerja Kaushik-Basu; Ramalingam Krishnan; Marc C Nicklaus; Ian F Thorpe
Journal:  Bioorg Med Chem       Date:  2013-03-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.